◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...
Customize Items

REGENERON PHARMACEUTICALS, INC.

CIK: 872589 SIC: 2834
$14.34B
Revenue
$4.50B
Net Income
85.35%
Gross Margin
24.95%
Op. Margin
$6.64B
Free Cash Flow
Financial Statements Quarterly (10-Q)
Showing 7 of 47 quarterly reports available
Breakdown Q4 2025
(Dec 31, 2025)
Q3 2025
(Sep 30, 2025)
Q2 2025
(Jun 30, 2025)
Q1 2025
(Mar 31, 2025)
Q4 2024
(Dec 31, 2024)
Q3 2024
(Sep 30, 2024)
Q2 2024
(Jun 30, 2024)
+ Total Revenue $3.88B $3.75B $3.68B $3.03B $3.79B $3.72B $3.55B
Revenue Growth % (YoY) 2.5% 0.9% 3.6% nan% nan% nan% nan%
Cost of Revenue $584.60M $521.60M $530.20M $464.30M $565.40M $491.10M $480.20M
+ Gross Profit $3.30B $3.23B $3.15B $2.56B $3.22B $3.23B $3.07B
Gross Margin % 84.9% 86.1% 85.6% 84.7% 85.1% 86.8% 86.5%
Operating Expenses $3.00B $2.73B $2.60B $2.44B $2.80B $2.54B $2.48B
Research & Development $1.63B $1.48B $1.42B $1.33B $1.41B $1.27B $1.20B
Selling General & Admin $775.00M $657.80M $634.20M $633.00M $792.20M $714.40M $758.80M
+ Operating Income $879.90M $1.03B $1.08B $591.70M $990.20M $1.18B $1.07B
Operating Margin % 22.7% 27.3% 29.4% 19.5% 26.1% 31.7% 30.2%
Interest Expense $10.00M $19.30M $3.60M $8.70M $7.90M $13.80M $14.80M
Other Income/Expense $176.00M $755.80M $442.80M $322.00M $-21.60M $327.30M $573.30M
Income Before Tax $1.04B $1.76B $1.52B $905.00M $958.10M $1.49B $1.63B
Income Tax Expense $199.10M $303.30M $127.10M $96.30M $40.40M $152.40M $195.80M
+ Net Income $844.60M $1.46B $1.39B $808.70M $917.70M $1.34B $1.43B
Net Margin % 21.7% 38.9% 37.9% 26.7% 24.2% 36.0% 40.4%
Basic EPS nan 14.09 13.24 7.58 8.54 12.40 13.25
Diluted EPS nan 13.62 12.81 7.27 8.11 11.54 12.41
Basic Shares Outstanding -500K 103.6M 105.1M 106.7M -100K 108.1M 108.1M
Diluted Shares Outstanding -300K 107.2M 108.6M 111.2M -500K 116.2M 115.4M
Breakdown Q4 2025
(Dec 31, 2025)
Q3 2025
(Sep 30, 2025)
Q2 2025
(Jun 30, 2025)
Q1 2025
(Mar 31, 2025)
Q4 2024
(Dec 31, 2024)
Q3 2024
(Sep 30, 2024)
Q2 2024
(Jun 30, 2024)
Cash & Cash Equivalents $3.12B $2.51B $2.00B $3.09B $2.49B $2.01B $1.92B
Short-term Investments $5.49B $5.94B $5.47B $5.26B $6.52B $7.78B $7.89B
Accounts Receivable $5.74B $5.69B $5.61B $5.56B $6.21B $6.11B $5.72B
Inventory $3.20B $3.25B $3.21B $3.19B $3.09B $3.02B $2.87B
Other Current Assets $474.80M $595.60M $574.30M $468.90M $349.20M $412.00M $681.90M
Total Current Assets $18.02B $17.98B $16.86B $17.57B $18.66B $19.33B $19.08B
Intangible Assets $1.26B $1.38B $1.35B $1.17B $1.15B $1.12B $1.10B
Long-term Investments $10.26B $10.29B $10.06B $9.28B $8.90B $8.49B $7.72B
Other Non-current Assets $1.82B $1.67B $1.54B $1.39B $1.14B $1.04B $993.80M
Total Assets $40.56B $40.17B $38.22B $37.55B $37.76B $37.44B $36.09B
Accounts Payable $939.00M $903.80M $723.90M $705.50M $789.50M $497.30M $561.70M
Deferred Revenue $553.00M $545.60M $481.90M $619.30M $627.70M $627.20M $586.00M
Total Current Liabilities $4.37B $4.43B $3.67B $3.57B $3.94B $3.66B $3.51B
Long-term Debt $1.99B $1.99B $1.99B $1.98B $1.98B $1.98B $1.98B
Other Non-current Liabilities $2.02B $1.86B $1.70B $1.67B $1.57B $1.54B $1.46B
Total Liabilities $9.30B $9.21B $8.28B $8.16B $8.41B $8.12B $7.88B
Retained Earnings $35.80B $35.05B $33.68B $32.38B $31.67B $30.76B $29.41B
Total Stockholders Equity $31.26B $30.96B $29.94B $29.39B $29.35B $29.33B $28.21B
Total Liabilities & Equity $40.56B $40.17B $38.22B $37.55B $37.76B $37.44B $36.09B
Breakdown Q4 2025
(Dec 31, 2025)
Q3 2025
(Sep 30, 2025)
Q2 2025
(Jun 30, 2025)
Q1 2025
(Mar 31, 2025)
Q4 2024
(Dec 31, 2024)
Q3 2024
(Sep 30, 2024)
Q2 2024
(Jun 30, 2024)
Net Income $844.60M $1.46B $1.39B $808.70M $917.70M $3.49B $1.43B
Depreciation & Amortization $145.00M $398.70M $262.00M $126.90M $126.40M $356.50M $234.80M
Stock-based Compensation $249.30M $744.40M $507.40M $255.70M $304.40M $678.40M $453.30M
Change in Receivables $51.20M $-549.30M $-629.60M $-657.80M $117.80M $436.20M $47.30M
Change in Inventory $-2.10M $277.40M $194.80M $152.30M $117.70M $502.00M $337.60M
Operating Cash Flow $1.17B $3.81B $2.19B $1.05B $1.26B $3.16B $1.87B
Capital Expenditure $248.70M $649.70M $448.30M $229.30M $199.60M $556.30M $314.40M
Acquisitions $300.00K $3.00M - - $11.50M $5.00M $5.00M
Purchases of Investments $2.04B $8.91B $5.39B $2.54B $1.95B $14.66B $10.07B
Investing Cash Flow $220.30M $-849.40M $-446.50M $647.50M $350.60M $-2.82B $-2.24B
Stock Issued $503.50M $132.40M $92.10M $60.60M $90.90M $1.37B $1.12B
Stock Repurchased $671.70M $2.77B $2.10B $1.04B $973.00M $1.63B $895.20M
Dividends Paid $92.70M $277.60M $186.40M $93.80M - - -
Financing Cash Flow $-780.10M $-2.94B $-2.22B $-1.09B $-1.14B $-1.06B $-431.00M
Net Change in Cash $610.60M $24.10M $-473.40M $604.00M $477.20M $-726.00M $-809.60M
SEC Filing Format - Data shown as it appears in the Q3 2025 (10-Q) filing Period ended: Sep 30, 2025
Condensed Consolidated Statements of Operations
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Total Revenue $3.75B - $10.46B -
Operating Expenses $2.73B - $7.76B -
Research & Development $1.48B - $4.22B -
Selling General & Admin $657.80M - $1.93B -
Operating Income $1.03B - $2.70B -
Interest Expense $19.30M - $31.60M -
Other Income/Expense $755.80M - $1.52B -
Income Before Tax $1.76B - $4.19B -
Income Tax Expense $303.30M - $526.70M -
Net Income $1.46B $1.43B $3.66B -
Basic EPS 14.09 - 34.83 -
Diluted EPS 13.62 - 33.61 -
Basic Shares Outstanding $103.60M - $105.10M -
Diluted Shares Outstanding $107.20M - $108.90M -
Condensed Consolidated Balance Sheets
Description Sep 30, 2025 Dec 31, 2024
Cash & Cash Equivalents $2.51B $2.49B
Short-term Investments $5.94B $6.52B
Accounts Receivable $5.69B $6.21B
Inventory $3.25B $3.09B
Other Current Assets $595.60M $349.20M
Total Current Assets $17.98B $18.66B
Intangible Assets $1.38B $1.15B
Long-term Investments $10.29B $8.90B
Other Non-current Assets $1.67B $1.14B
Total Assets $40.17B $37.76B
Accounts Payable $903.80M $789.50M
Deferred Revenue $545.60M $627.70M
Total Current Liabilities $4.43B $3.94B
Long-term Debt $1.99B $1.98B
Other Non-current Liabilities $1.86B $1.57B
Total Liabilities $9.21B $8.41B
Retained Earnings $35.05B $31.67B
Total Stockholders Equity $30.96B $29.35B
Total Liabilities & Equity $40.17B $37.76B
Condensed Consolidated Statements of Cash Flows
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Net Income $1.46B $1.43B $3.66B -
Depreciation & Amortization - - $398.70M -
Stock-based Compensation - - $744.40M -
Change in Receivables - - $-549.30M -
Change in Inventory - - $277.40M -
Operating Cash Flow - - $3.81B -
Capital Expenditure - - $649.70M -
Acquisitions - - $3.00M -
Purchases of Investments - - $8.91B -
Investing Cash Flow - - $-849.40M -
Stock Issued - - $132.40M -
Stock Repurchased - - $2.77B -
Dividends Paid - - $277.60M -
Financing Cash Flow - - $-2.94B -
Net Change in Cash - - $24.10M -

All values are in USD (United States Dollars). Data is sourced from SEC EDGAR 10-Q filings.

Quarterly data represents single quarter results (Q1-Q4). Some items may show year-to-date values if quarterly breakdown is unavailable.

NEWS
Loading article...
NEWS
Loading news...
TRENDING
Loading...